323 results
SC TO-C
EX-99.1
INCY
Incyte Corp.
13 May 24
Information about tender offer
7:19am
or strategic activities; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable
8-K
EX-99.1
INCY
Incyte Corp.
13 May 24
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
7:18am
or strategic activities; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable
8-K
EX-99.1
INCY
Incyte Corp.
30 Apr 24
Incyte Reports 2024 First Quarter Financial Results and Provides Updates
7:10am
cost of product revenues
Non-GAAP cost of product revenues1
GAAP research and development
Non-GAAP research and development2
GAAP selling, general … of the European business of ARIAD Pharmaceuticals, Inc. and the cost of stock-based compensation.
2 Non-GAAP research and development expenses exclude
S-8
EX-99.1
2my5aem3f1y5ip96n
13 Feb 24
Registration of securities for employees
5:06pm
8-K
EX-99.1
vbpt9f30cge13bhl
13 Feb 24
Provides 2024 Financial Guidance and Highlights R&D Priorities
7:03am
8-K
EX-99.1
7ijj2ffc38zb7
31 Oct 23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates
7:05am
8-K
EX-99.1
hg9poipa7ia4fvtx1
1 Aug 23
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates
7:05am
8-K
EX-10.1
z0vuds el
15 Jun 23
Departure of Directors or Certain Officers
2:10pm
8-K
sejr6 7o4mro
8 May 23
Other Events
5:21pm
8-K
EX-99.1
vkqf88j8412js1gah
2 May 23
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
7:01am